Q3 EPS Forecast for Allogene Therapeutics Lifted by Analyst

Key Points

• Zacks Research has increased its Q3 2025 earnings estimate for Allogene Therapeutics to ($0.23) per share from a previous forecast of ($0.24).
• Allogene Therapeutics reported ($0.23) EPS for the last quarter, beating the consensus estimate of ($0.28) by $0.05.
• Price targets for Allogene Therapeutics have been adjusted by various analysts, with Citigroup lowering it from $8.00 to $4.00 while still maintaining a "buy" rating.

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Zacks Research lifted their Q3 2025 earnings estimates for Allogene Therapeutics in a report issued on Wednesday, September 3rd. Zacks Research analyst Team now forecasts that the company will earn ($0.23) per share for the quarter, up from their previous estimate of ($0.24). The consensus estimate for Allogene Therapeutics' current full-year earnings is ($1.28) per share. Zacks Research also issued estimates for Allogene Therapeutics' FY2025 earnings at ($0.96) EPS, Q1 2026 earnings at ($0.23) EPS, Q2 2026 earnings at ($0.23) EPS, FY2026 earnings at ($0.96) EPS, Q1 2027 earnings at ($0.25) EPS, Q2 2027 earnings at ($0.24) EPS and FY2027 earnings at ($0.98) EPS.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.05.

Other analysts have also recently issued research reports about the stock. Wall Street Zen raised shares of Allogene Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 30th. JMP Securities reaffirmed a "market perform" rating on shares of Allogene Therapeutics in a report on Monday, August 4th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $10.00 target price on shares of Allogene Therapeutics in a report on Wednesday, May 14th. Truist Financial reduced their target price on shares of Allogene Therapeutics from $14.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Finally, Oppenheimer cut their price objective on shares of Allogene Therapeutics from $10.00 to $9.00 and set an "outperform" rating on the stock in a report on Wednesday, May 14th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $8.44.

Allogene Therapeutics Stock Performance

Shares of ALLO traded up $0.04 during mid-day trading on Friday, hitting $1.15. 2,348,697 shares of the company's stock were exchanged, compared to its average volume of 3,786,546. The company has a market cap of $255.16 million, a price-to-earnings ratio of -1.04 and a beta of 0.36. Allogene Therapeutics has a fifty-two week low of $0.86 and a fifty-two week high of $3.78. The stock's 50-day moving average is $1.19 and its 200-day moving average is $1.38.

Hedge Funds Weigh In On Allogene Therapeutics

A number of hedge funds have recently modified their holdings of ALLO. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Allogene Therapeutics during the first quarter worth approximately $28,000. Caption Management LLC purchased a new position in shares of Allogene Therapeutics during the fourth quarter worth approximately $32,000. CANADA LIFE ASSURANCE Co grew its position in shares of Allogene Therapeutics by 142.0% during the second quarter. CANADA LIFE ASSURANCE Co now owns 31,211 shares of the company's stock worth $35,000 after acquiring an additional 18,314 shares during the last quarter. R Squared Ltd purchased a new position in shares of Allogene Therapeutics during the second quarter worth approximately $37,000. Finally, Engineers Gate Manager LP purchased a new position in shares of Allogene Therapeutics during the second quarter worth approximately $37,000. 83.63% of the stock is currently owned by hedge funds and other institutional investors.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).